Behind Global Blood and Novartis, Bluebird leads a pack of biotechs wanting a slice of the sickle cell disease market.
Launch phase is a challenging time for drug developers, so consider the likes of Biohaven, Esperion and, most recently, Urogen, as they brave locked-down markets.
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.
Using drugs that can cause or exacerbate lung infections to treat the novel coronavirus – what could go wrong?
The fragile X pipeline is strewn with failures, and crunch time is approaching for Zynerba’s cannabinoid.
The US regulator granted 14 accelerated approvals in 2019, fewer than in the previous two years, and the sector remains slow at conversions.